Correction to: *Scientific Reports* 10.1038/s41598-018-26577-0, published online 24 May 2018

This Article and the accompanying Supplementary Information file contain errors.

In Figure 2, the wrong µM symbol was used. The correct Figure 2 appears below as Figure [1](#Fig1){ref-type="fig"}.Figure 1Radioligand binding assays and functional assays showed that SAA and SAC can bind and antagonize both P2Y~1~ and P2Y~12~ receptors, while SAB can bind and antagonize only the P2Y~12~ receptor. (**a**) Displacement curves of SAA, SAB and SAC against \[^3^H\]2MeSADP binding to the P2Y~12~ receptor. (**b**) Functional antagonism by SAA of 2MeSADP-induced inhibition of foskolin-stimulated cAMP accumulation in U2OS cells expressing the P2Y~12~ receptor. (**c**) Schild plots of the antagonism of SAA, SAB and SAC at the P2Y~12~ receptors. (**d**) Displacement curves of SAA, SAB and SAC against \[^3^H\]2MeSADP binding to the P2Y~1~ receptor. (**e**) 2MeSADPinduced IP-1 accumulation in U2OS cells expressing the P2Y~1~ receptor (compared to MRS2500). (**f**) Schild plots of antagonism by SAA and SAC at the P2Y~1~ receptor. Results are expressed as mean ± SEM. The K~i~ values from binding experiments and K~B~ values from Schild analyses of functional antagonism by SAA, SAB and SAC are listed in the text and are from at least three independent experiments. MRS, MRS2500; SAR, SAR216471.

In the Supplementary Information file, the title of Table S1 is incorrectly given as 'SAA, SAB and SAC are not promiscuously binding compounds'. The correct Table S1 appears below as Table [1](#Tab1){ref-type="table"}.Table 1Targets used in the off-target activities tested by the PDSP.\#Protein name\#Protein name15-HT~1A~24D~3~25-HT~1B~25D~4~35-HT~1D~26D~5~45-HT~1E~27GABA~A~55-HT~2A~28H~1~65-HT~2B~29H~2~75-HT~2C~30H~3~85-HT~3~31H~4~95-HT~5A~32M~1~105-HT~6~33M~2~115-HT~7~34M~3~12α~1A~35M~4~13α~1B~36M~5~14α~1D~37δ-opioid15α~2A~38κ-opioid16α~2B~39μ-opioid17α~2C~40σ~1~18β~1~41σ~2~19β~2~42DAT20β~3~43NET21BZP rat brain site44SERT22D~1~45TSPO23D~2~

Finally, in the Supplementary Information file, there is a typographical error in Figure S4 and its accompanying legend where 'Epinenohrineon' should read 'Epinephrine'. The correct Figure S4 appears below as Figure [2](#Fig2){ref-type="fig"}.Figure 2The functional activity of SAB on the adrenergic α~1B~ receptor were tested by FLIPR assays. SAB did not show agonist activity on α~1B~, epinephrine is a control agonist (EC50 29.8 nM) (**a**). SAB did not show antagonist activity on α~1B~, WB4104 is a control antagonist (IC50 4.51 nM) (**b**).
